

41. Olson MM, Lee JT Jr. Continuous, 10-year wound infection surveillance: results, advantages, and unanswered questions. *Arch Surg* 1990;125:794-803.
42. Condon RE, Schulte WJ, Malangoni MA, Anderson-Teschendorf MJ. Effectiveness of a surgical wound surveillance program. *Arch Surg* 1983;118:303-307.
43. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. *Am J Infect Control* 1992;20:271-274.
44. Society for Hospital Epidemiology of America, Association for Practitioners in Infection Control, Centers for Disease Control, Surgical Infection Society. Consensus paper on the surveillance of surgical wound infections. *Infect Control Hosp Epidemiol* 1992;13:599-605.
45. Altemeier WA, Burke JF, Sandusky WR. *Manual on Control of Infection in Surgical Patients*. Philadelphia, PA: JB Lippincott Co; 1984.
46. Gulácsi L, Kis ST, Goldmann DA, Huskins WC. Surgical site infection rates for frequently performed procedures in Hungarian hospitals. *Infect Control Hosp Epidemiol* 1997;18:P26. Abstract.
47. Sellick JA. The use of statistical process control charts in hospital epidemiology. *Infect Control Hosp Epidemiol* 1993;14:649-656.
48. Kaminsky FC, Benneyan JC, Davis RB, Burke RJ. Statistical control charts based on a geometric distribution. *Journal of Quality Technology* 1992;24:63-69.
49. Zaza S, Jarvis WR. Investigation of outbreaks. In: Mayhall CG, ed. *Hospital Epidemiology and Infection Control*. Baltimore: Williams & Wilkins; 1995:105-113.
50. Jacquez GM, Waller LA, Grimson R, Wartenberg D. The analysis of disease clusters, part I: state of the art. *Infect Control Hosp Epidemiol* 1996;17:319-327.
51. Jacquez GM, Grimson R, Waller LA, Wartenberg D. The analysis of disease clusters, part II: introduction to techniques. *Infect Control Hosp Epidemiol* 1996;17:385-397.
52. Mayhall CG. *Surgical infections including burns*. In: Wenzel RP, ed. *Prevention and Control of Nosocomial Infections*, 2nd ed. Baltimore, MD: Williams & Wilkins; 1993:614-664.
53. Durbin W Jr., Lapidus B, Goldmann DA. Improved antibiotic usage following introduction of a novel prescription system. *JAMA* 1981;246:1796-1800.
54. Kritchevsky SB, Simmons BP. Continuous quality improvement: concepts and applications for physician care. *JAMA* 1991;266:1817-1823.
55. National Nosocomial Infections Surveillance System. Nosocomial infection rates for interhospital comparison: limitations and possible solutions. *Infect Control Hosp Epidemiol* 1991;12:609-621.
56. National Nosocomial Infections Surveillance System. National Nosocomial Infection Surveillance (NNIS) semi-annual report, May 1995. *Am J Infect Control* 1995;23:377-385.

## Enterococci Intrinsically Resistant to Vancomycin

Gina Pugliese, RN, MS

Martin S. Favero, PhD

Investigators from Ottawa General Hospital, University of Ottawa, Ontario, Canada, conducted a prospective study of intrinsically vancomycin-resistant enterococci (VanC VRE). Constitutive low-level vancomycin resistance is found intrinsically in certain enterococcal species and is encoded by *vanC* ligase genes. VanC VRE were recovered from the stools of 34 (5.7%) of 601 patients, a rate similar to that obtained from the stools of 100 outpatients in the community (5%). VanC VRE also were isolated from the non-stool specimens of

9 (1.7%) of 538 patients, including two patients with bacteremia. No VRE of the *vanA* or *vanB* genotypes were detected in non-stool specimens. Eighty-two hospital contacts of the first 23 patients found to be colonized or infected with VanC VRE were screened, and 6 contacts were found to be gastrointestinal carriers of VanC VRE. However, typing of isolates by pulsed-field gel electrophoresis from these 6 contacts showed the isolates to be unique and different from those recovered from the index patients. In fact, all VanC VRE isolates from different patients in this study were unique.

A case-control study with patients who were negative when

screened for VanC VRE as controls failed to identify any risk factor associated with colonization or infection with this organism. VanC VRE were recovered infrequently from clinical specimens, but occasionally were found as part of the normal stool flora. Because no transmission between patients was documented, additional isolation procedures may not be necessary for patients colonized or infected with VanC VRE.

FROM: Toye B, Shymanski J, Bobrowska M, Woods W, Ramotar KJ. Clinical and epidemiological significance of enterococci intrinsically resistant to vancomycin. *J Clin Microbiol* 1997;35:3166-3170.